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SUMMARY
Mammalian DNA methylation is a critical epigenetic mechanism orchestrating gene expression 
networks in many biological processes. However, investigation of the functions of specific 
methylation events remains challenging. Here, we demonstrate that fusion of Tet1 or Dnmt3a with 
a catalytically inactive Cas9 (dCas9) enables targeted DNA methylation editing. Targeting of the 
dCas9-Tet1 or -Dnmt3a fusion protein to methylated or unmethylated promoter sequences caused 
activation or silencing, respectively, of an endogenous reporter. Targeted demethylation of the 
BDNF promoter IV or the MyoD distal enhancer by dCas9-Tet1 induced BDNF expression in 
post-mitotic neurons or activated MyoD facilitating reprogramming of fibroblasts into myoblasts, 
respectively. Targeted de novo methylation of a CTCF loop anchor site by dCas9-Dnmt3a blocked 
CTCF binding and interfered with DNA looping, causing altered gene expression in the 
neighboring loop. Finally, we show that these tools can edit DNA methylation in mice 
demonstrating their wide utility for functional studies of epigenetic regulation.
Graphical Abstract
6,7Correspondence should be addressed to Rudolf Jaenisch as the Lead Contact, jaenisch@wi.mit.edu, Phone: 617-258-5186.
3Present address: School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China
5These authors contributed equally to this work
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Author Contributions
X.S.L. and R.J. conceived the idea for this project. X.S.L. and H.W. designed and conducted the experiments and interpreted the data. 
X.J. performed ChIP and 3C assay, Y.S. generated Snrpn-GFP reporter ES cell lines and IG-DMRGFP/Pat reporter mice. S.C., X.W. 
and J.S. assisted with sequencing analysis. X.S.L., H.W. and R.J. wrote the manuscript with inputs from all the other authors.
HHS Public Access
Author manuscript
Cell. Author manuscript; available in PMC 2017 September 22.
Published in final edited form as:
Cell. 2016 September 22; 167(1): 233–247.e17. doi:10.1016/j.cell.2016.08.056.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
Mammalian DNA methylation at 5-cytosine plays critical roles in many biological 
processes, including genomic imprinting, cell fate determination, chromatin architecture 
organization, and regulation of gene expression (Bird, 2002; Jaenisch and Bird, 2003; Smith 
and Meissner, 2013). Genetic studies have revealed that DNA methylation is essential for 
mammalian development and adaptation to environmental signals (Jaenisch and Bird, 2003). 
Abnormal DNA methylation has been observed in cancer and neurological disorders 
(Robertson, 2005). Owing to the advancement in sequencing technologies, single-nucleotide 
resolution methylation maps for many types of human and mouse cells and tissues have been 
depicted (Lister et al., 2013; Lister et al., 2009). Importantly, these maps have allowed for 
the identification of differentially methylated regions (DMRs) at base pair resolution during 
different stages of normal development as well as disease (De Jager et al., 2014; Landau et 
al., 2014). However, investigation of the functional significance of these DMRs remains a 
challenge due to lack of appropriate molecular tools that enable efficient editing of DNA 
methylation in a targeted manner.
We set out to establish such a toolbox by hybridization of the key enzymes in DNA 
methylation pathway with reprogrammable sequence-specific DNA-targeting molecular 
machinery. DNA methylation is established by two de novo DNA methyltransferases 
(Dnmt3a/b), and is maintained by Dnmt1 (Smith and Meissner, 2013). Gene activation 
during development is associated with demethylation of promoter and enhancer sequences 
with the best-understood mechanism being passive demethylation by inhibition of Dnmt1. In 
addition, demethylation can be achieved through oxidation of the methyl group by TET (ten-
eleven translocation) dioxygenases to form 5-hydroxymethylcytosine (5-hmC), and then 
restoration into unmodified cytosines by either DNA replication-dependent dilution or DNA 
glycosylase-initiated base excision repair (BER), a process termed as active demethylation 
and proposed to operate during specific developmental stages such as preimplantation 
embryos or in post-mitotic neurons (Wu and Zhang, 2014).
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Clustered regularly interspaced palindromic repeats (CRISPR), a type II bacterial adaptive 
immune system, has been modified to target the Cas9 nuclease to desired genomic loci with 
sequence-specific guide RNAs for genome editing (Cong et al., 2013; Jinek et al., 2012; 
Mali et al., 2013). Importantly, a catalytically inactive Cas9 (dCas9) was generated and 
engineered in several systems as a DNA targeting module to bring effector proteins such as 
transcriptional activator/suppressor, chromatin modifier, and green fluorescence protein to 
regulate gene expression, to modify chromatin, and to image genomic loci respectively 
(Chen et al., 2013; Gilbert et al., 2013; Hilton et al., 2015; Jinek et al., 2012; Konermann et 
al., 2015; Qi et al., 2013).
In this study, we demonstrate that fusion of dCas9 with the Tet1 enzymatic domain or 
Dnmt3a allows for targeted erasure or establishment of DNA methylation, respectively. As a 
proof of principle, we first induced alterations to DNA methylation in two synthetic 
methylation reporters integrated in mouse embryonic stem cells (mESCs). Our results show 
that targeted demethylation of BDNF promoter IV is sufficient to activate its expression in 
mouse cortical neurons, and that targeted demethylation of a MyoD distal enhancer 
promotes reprogramming of fibroblasts into myoblasts and facilitates myotube formation. 
With dCas9-Dnmt3a, we demonstrate that targeted methylation at CTCF binding sites is able 
to block CTCF recruitment and to alter the expression of genes in the neighborhood loop by 
increasing their interaction frequencies with the super-enhancers insulated in the targeted 
loops. Furthermore, lentiviral delivery of dCas9-Tet1 with target gRNAs into mice enabled 
in vivo activation of a methylation reporter by demethylation of its promoter. Thus, dCas9-
Tet1 and dCas9-Dnmt3a provide powerful tools to investigate the functional significance of 
DNA methylation in a locus-specific manner.
RESULTS
A modified CRISPR system to edit DNA methylation
To achieve targeted editing of DNA methylation, we fused dCas9 with enzymes in the 
methylation/demethylation pathway (Fig 1A). Based on previous studies using the TALE 
system to target specific CpGs (Bernstein et al., 2015; Maeder et al., 2013), Tet1 and 
Dnmt3a were chosen as the effectors in our system. Co-expression of sequence-specific 
guide RNA (gRNA) would be expected to target dCas9-Tet1 or dCas9-Dnmt3a to the 
specific locus and mediate modification of DNA methylation status without altering the 
DNA sequence. To optimize this chimeric CRISPR/dCas9-effector system, we tested two 
types of dCas9-Tet1 lentiviral constructs with nuclear localization signal (NLS) at different 
positions: dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1 (Fig S1A and S1B). We also tested 
two types of gRNA lentiviral constructs, a widely used chimeric single-guide RNA referred 
as gRNA (Jinek et al., 2012) and a modified guide RNA with enhanced capacity to guide 
Cas9 to the designed genomic locus referred as E-gRNA (Chen et al., 2013). Both gRNA 
constructs contain a puro selection cassette and a Cherry fluorescence protein cassette driven 
by an independent CMV promoter that allows for Fluorescence Activated Cell Sorting 
(FACS) of gRNA-expressing cells after lentiviral transduction (Fig S1A). Characterization 
of these constructs showed a robust gRNA-induced nuclear translocation for the dCas9-
NLS-Tet1 construct (Fig S1C–E), and thus this construct was chosen for all experiments in 
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order to minimize non-specific modifications of DNA. Two types of gRNA behaved 
similarly (Fig S1C–E) and thus were used interchangeably.
dCas9-Tet1 and dCas9-Dnmt3a enable targeted alterations of CpG methylation state
To assess whether the dCas9-Tet1 and -Dnmt3a fusion constructs would induce 
demethylation or de novo methylation, respectively, of specific sequences, we utilized a 
methylation reporter system previously developed in our laboratory (Stelzer et al., 2015). 
This reporter system consists of a synthetic methylation-sensing promoter (conserved 
sequence elements from the promoter of an imprinted gene, Snrpn) that controls the 
expression of a green fluorescence protein (GFP). Insertion of this reporter construct into a 
genomic locus was shown to faithfully report on the methylation state of the adjacent 
sequences (Stelzer et al, 2015).
a. Demethylation of specific CpGs—To test whether defined sequences could be 
demethylated, we introduced the dCas9-Tet1 construct in combination with gRNAs to target 
the Snrpn-GFP reporter inserted into the Dazl promoter (Fig 1B and Fig S2A). Dazl is a 
germ cell specific gene, which is hypermethylated and not active in ES cells, and thus the 
GFP reporter is not expressed. To activate GFP expression by dCas9-Tet1 we designed 4 
gRNAs targeting all 14 CpGs in the Snrpn promoter region. After infection with lentiviral 
vectors co-expressing dCas9-Tet1 and the 4 gRNAs for three days, some infection-positive 
cells as labeled by Cherry positive signal expressed from gRNA construct began to turn on 
GFP (Fig S2B). To assess the activation efficiency by dCas9-Tet1 with target gRNAs, we 
analyzed the cells infected by both viruses using FACS. Among the Cherry positive 
population, about 26% of cells with target gRNAs activated GFP, whereas only 1% of cells 
with a scrambled gRNA were GFP positive (Fig 1C and Fig S2C). These Cherry positive 
single cells were further cultured to allow for formation of ES cell colonies. Cells with target 
gRNAs, but not the scrambled gRNA, expressed GFP (Fig 1D). To confirm that the 
activation of GFP in these cells is caused by demethylation of the Snrpn promoter, we 
performed bisulfite sequencing of genomic DNA from these samples. As illustrated in Fig 
1E and 1F, samples from cells with target gRNAs showed robust demethylation only in the 
Snrpn promoter region but not the adjacent Dazl locus, and samples from the cells with the 
scrambled gRNA showed a similar methylation status to the uninfected (Mock) control. We 
further analyzed the GFP-positive and -negative populations within infected Cherry-positive 
cells. As shown in Fig S2D, a more robust demethylation of the Snrpn promoter region was 
observed in double positive cells (Cherry+;GFP+). These results confirm the targeted erasure 
of DNA methylation by dCas9-Tet1 with gRNAs in proliferative cells.
b. De novo methylation of specific CpGs—To assess whether a dCas9-Dnmt3a fusion 
protein could de novo methylate promoter sequences and silence gene expression, we used 
cells carrying the Snrpn-GFP reporter in the Gapdh promoter. These cells are GFP positive 
because Gapdh is unmethylated and expressed in ES cells (Stelzer et al., 2015). We infected 
the Gapdh-Snrpn-GFP ESCs with lentiviruses expressing dCas9-Dnmt3a and gRNAs 
targeting the Snrpn promoter or a scrambled gRNA (Fig 2A and Fig S2E), followed by 
FACS analysis. Among infection-positive (Cherry positive) population, about 12% of cells 
with target gRNAs inactivated GFP, whereas only 2% of cells with the scrambled gRNA 
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were GFP negative (Fig 2B and S2F). When the Cherry positive cells were grown in culture, 
GFP expression of cells with target gRNAs remained off whereas cells with the scrambled 
gRNA and mock controls remained GFP positive (Fig 2C). Furthermore, bisulfite 
sequencing showed that transduction of dCas9-Dnmt3a/gRNAs resulted in a significant 
increase of DNA methylation in the Snrpn promoter region but not in the adjacent Gapdh 
region (Fig 2D and 2E). Further analysis of the GFP-positive and -negative populations 
within infected Cherry-positive cells showed a more robust methylation of the Snrpn 
promoter region in Cherry+;GFP- cells (Fig S2G). To overcome the possible limitation 
caused by low co-transduction efficiency of both dCas9-Dnmt3a and gRNA lentiviruses, a 
Doxycycline-inducible dCas9-Dnmt3a expression cassette was integrated into the Gapdh-
Snrpn-GFP mES cell line by using a PiggyBac transposon system (Fig S2H). After delivery 
of the same group of target gRNAs, FACS analysis showed that GFP inactivation efficiency 
was increased to 25% (Fig 2F and S2I). Sorted Cherry-positive cells showed loss of GFP 
expression upon Doxycycline treatment (Fig 2G) and were robustly methylated in the Snrpn 
promoter region (Fig 2H). We also generated a new construct of dCas9-Dnmt3a-P2A-BFP 
which enables isolation of dCas9-Dnmt3a expressing cells by FACS. ~70% of GFP 
inactivation efficiency was achieved in FACS sorted double positive cells (BFP+;Cherry+) 
after lentiviral delivery of this construct together with gRNAs (Fig S2J).
In summary, our results indicate that the dCas9 fusion constructs described above either 
efficiently demethylate methylated sequences (dCas9-Tet1) or de novo methylate 
unmethylated sequences (dCas9-Dnmt3a) in dividing cells when targeted by specific guide 
RNAs.
Comparison of dCas9- and TALE-based methylation editing
To compare the methylation editing efficacy and effective range by dCas9-Tet1/Dnmt3a with 
TALE-based methods, we chose two previously reported loci edited by TALE-based method 
(Bernstein et al., 2015; Maeder et al., 2013) and designed a single gRNA targeting dCas9-
Tet1/Dnmt3 to the same site bound by the TALE-Tet1/Dnmt3a. As shown in Fig S3A and 
S3C, dCas9-Dnmt3a with one single gRNA targeting the p16 locus induced an average of 
25% increase of methylation within a 320 bp region of the p16 promoter whereas TALE-
Dnmt3a only induced 13% increase within a 650 bp region. Similarly, dCas9-Tet1 with one 
single gRNA targeting the RHOXF2 locus induced an average of 28% decrease of 
methylation within a 150 bp region of the RHOXF2 promoter whereas TALE-Tet1 only 
induced 14% decrease within a 200 bp region (Fig S3B and S3C). These results suggest that 
dCas9-Tet1/Dnmt3a system has higher efficacy and resolution for methylation editing than 
TALE-based method.
To evaluate the specificity of dCas9-Tet1/Dnmt3a-mediated methylation editing, we 
performed dCas9 ChIP-seq assay and identified 9 binding sites in the presence of gRNAs 
targeting the Dazl-Snrpn region described in Fig S2A and 18 binding sites in the presence of 
gRNAs targeting CTCF binding sites adjacent to the miR290 locus (see below Fig S6A). Fig 
S3D shows that among the identified binding sites for each group of gRNAs, the targeted 
locus (Dazl-Snrpn or miR290) showed the highest level of binding for dCas9-Dnmt3a (Table 
S1). The second and third strongest binding sites for each targeted locus were illustrated in 
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Fig S3E, and bisulfite sequencing analysis of these loci showed only marginal change in 
methylation level (Fig S3F and S3G), likely due to the significantly lower binding affinity of 
dCas9-Dnmt3a/Tet1 at these off-target loci compared to the targeted loci. These results 
indicate that dCas9-based epigenetic editing can be highly specific.
Targeted demethylation of BDNF promoter IV activates BDNF in neurons
DNA replication-independent active demethylation has been proposed to operate in post-
mitotic neurons (Guo et al., 2011; Martinowich et al., 2003). To test whether active 
demethylation can be induced in post-mitotic neurons, we applied the dCas9-Tet1 system to 
study the regulation of the BDNF gene. BDNF expression can be induced by neuronal 
activity accompanied by demethylation of its promoter IV (Chen et al., 2003; Martinowich 
et al., 2003). We designed 4 gRNAs targeting 11 CpGs in BDNF promoter IV (Fig S4A) to 
determine whether dCas9-Tet1 can activate BDNF by inducing demethylation of this 
promoter (Fig 3A). Mouse cortical neurons were isolated from E17.5 embryos and cultured 
for two days in vitro (DIV2) following a well-established experimental procedure for 
producing primary neuronal culture (Ebert et al., 2013). As shown in Fig S4B–D, KCl 
treatment induced BDNF expression in these neurons with no detectable cell proliferation. 
Neurons at day 3 in culture (DIV3) were infected with lentiviral vectors expressing dCas9-
Tet1 with or without the 4 gRNAs at almost 100% transduction efficiency (Fig S4E). At 48-
hour post infection some of the cultures were treated with KCl to induce neuronal activity. 
As shown in Fig 3B and 3C, dCas9-Tet1/gRNAs induced BDNF expression by about 6-fold, 
whereas dCas9-Tet1 in the absence of gRNAs showed only a slight induction (less than 2-
fold) and a catalytically dead form of Tet1 (dC-dT) showed no induction. Importantly, the 
same group of dCas9-Tet1/gRNAs did not induce Npas4 expression (Fig S4F), another 
neuronal activity-inducible gene (Lin et al., 2008). Co-transduction of dCas9-Tet1 with each 
individual gRNA targeting the BDNF promoter IV showed a 2–3 fold induction of BDNF 
(Fig S4G). We performed bisulfite sequencing to examine the methylation state of BDNF 
promoter IV. As shown in Fig 3D and 3E, dCas9-Tet1/gRNAs significantly reduced 
methylation in this region in contrast to gRNA negative controls while KCl treatment also 
induced demethylation of CpGs at positions of −148, −66 and 19 (relative to transcription 
start site).
Our results demonstrate that demethylation of the BDNF promoter IV can be induced by 
dCas9-Tet1/gRNAs and is sufficient to activate BDNF expression. Because post-mitotic 
neurons were used for these experiments, loss of methylation was likely due to active 
demethylation. To further support this conclusion, we examined 5-hmC level in the BDNF 
promoter IV during the time course of dCas9-Tet1 induced demethylation by Tet-assisted 
Bisulfite sequencing (TAB-seq) analysis. As shown in Fig S4H, 5-hmC was detected 40-
hour post infection with dCas9-Tet1 and gRNA lentiviruses and diminished after 60 hours. 
Similarly, 5-hmC was also detected after KCl treatment (Fig S4I). As bisulfite sequencing 
method does not distinguish unmethylated 5-cytosine (5-C) and 5-formlycytosine/5-
carboxylcytosin (5-fC/5-caC) generated from 5-hmC, it is possible that some CpGs were 5-
fC/5-caC modified after targeting with dCas9-Tet1/gRNA. Nevertheless, inhibition of the 
base excision repair pathway by treatment with ABT-888 (an inhibitor of PARP) reduced the 
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activation of BDNF by KCl treatment (Fig S4J), suggesting that demethylation of BDNF 
promoter IV contributes to BDNF activation.
To test whether endogenous Tet activity was required to regulate BDNF expression upon 
neuronal activity stimulation, we treated DIV3 neurons with 2-hydroxygluterate, a 
competitive inhibitor for α-ketoglutarate-dependent dioxygenases including Tet enzymes 
(Xu et al., 2011). As shown in Fig S4K, pharmacological inhibition of Tet enzymatic activity 
completely abolished the induction of BDNF expression by KCl treatment. Furthermore, 
mouse primary cortical neurons carrying a Tet1 null mutant showed significantly attenuated 
activation kinetics of BDNF (Fig S4L), supporting a role of endogenous Tet for induction of 
neuronal activity.
Targeted demethylation of the MyoD distal enhancer facilitates myogenic reprogramming 
of fibroblasts
The role of MyoD as a master regulator for muscle development was initially defined by the 
observations that demethylation of DNA in fibroblasts by 5-Aza (5-Aza-2’-deoxycytidine) 
treatment resulted in activation of MyoD and subsequent myoblast conversion and myotube 
formation (Constantinides et al., 1977; Davis et al., 1987; Lassar et al., 1986). Six muscle-
specific DMRs have been described within the 50 kb upstream region of MyoD gene 
(Schultz et al., 2015), and DMR-5 overlaps with a known distal enhancer of MyoD (Brunk 
et al., 1996) as shown in Fig 4A. To test whether demethylation of DMR-5 would activate 
MyoD in fibroblasts, we designed 4 gRNAs targeting this DMR (Fig S5A). Co-expression of 
dCas9-Tet1 with these gRNAs in C3H10T1/2 cells, a sub-clone from mouse embryonic 
fibroblasts previously used for 5-Aza mediated MyoD activation (Constantinides et al., 
1977), resulted in a moderate induction of MyoD expression (3-fold) as shown in Fig 4B. 
Combination of dCas9-Tet1/MyoD DMR-5 gRNAs with 5-Aza treatment resulted in a 
higher induction of MyoD as shown in Fig S5F. Bisulfite sequencing showed a substantial 
reduction of methylation in the DMR-5 region of sorted infection-positive cells transduced 
with dCas9-Tet1 and target gRNAs lentiviruses, but not with a catalytically dead Tet1 (dC-
dT) or a scrambled gRNA (Fig 4C and 4D). To investigate whether demethylation of the 
MyoD distal enhancer region could reprogram fibroblasts into muscle cells, we infected 
C3H10T1/2 cells with lentiviruses expressing dCas9-Tet1 and gRNAs. The cells were 
cultured for 14 days and analyzed for MyoD and MHC (Myosin Heavy chain, a myotube 
specific marker) expression. As shown in Fig 4E and 4F, co-expression of dCas9-Tet1 with 
gRNAs targeting DMR-5 induced a moderate expression level of MyoD, but was not 
sufficient to induce myotube formation in the absence of 5-Aza treatment.
We then investigated whether targeted demethylation of DMR-5 would synergize with 5-Aza 
treatment to induce myotube formation (Fig S5B). To follow the process of myotube 
formation after 5-Aza treatment, a time-course experiment was performed. Multi-nucleated 
myotube (MHC-positive) with heterogeneous sizes began to form 14 days post treatment, 
and both MyoD-positive cell ratio and myotube density and size then increased up to day-25 
(Fig S5C–E). Co-expression of dCas9-Tet1 with gRNAs targeting MyoD DMR-5 facilitated 
the myotube formation 14 days post-treatment as evidenced by significantly more mature, 
multi-nucleated MHC+ clusters (>2 nuclei per MHC+ cluster) compared to cells expressing 
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only dCas9-Tet1 or dC-dT with MyoD DMR-5 gRNAs (Fig 4E, 4G, and 4H). A similar 
observation was made when the cells were analyzed at a later time point (16-day) post-
treatment (Fig S5G–J). Our results suggest that demethylation of the MyoD distal enhancer 
by dCas9-Tet1/gRNA synergizes with 5-Aza in C3H10T1/2 cells to substantially facilitate 
myoblast conversion and myotube formation.
Targeted de novo methylation of CTCF binding sites alters CTCF-mediated chromatin 
loops
CTCF is a highly conserved zinc finger protein that plays a primary role in the global 
organization of chromatin architecture (Phillips and Corces, 2009). Transcriptional 
enhancers normally interact with their target genes through the formation of DNA loops 
(Gibcus and Dekker, 2013; Gorkin et al., 2014; Kagey et al., 2010), which typically are 
constrained within larger CTCF-mediated loops called insulated neighborhoods (Dowen et 
al., 2014; Ji et al., 2016; Phillips-Cremins et al., 2013), which in turn can form clusters of 
loops that contribute to topologically associating domains (TADs) (Dixon et al., 2012; Nora 
et al., 2012). Deletion of the CTCF loop anchor sites of insulated neighborhoods can cause 
enhancers to interact inappropriately with genes located outside the loop and thus increase 
their expression (Dowen et al., 2014). Interestingly, methylation of the DNA recognition site 
of CTCF has been reported to block CTCF binding (Bell and Felsenfeld, 2000; Wang et al., 
2012). To study whether methylation of specific CTCF sites could alter CTCF-mediated 
chromatin loops, we applied the dCas9-Dnmt3a system to target CTCF anchor sites (Fig 
5A). We designed specific gRNAs (Fig S6) targeting dCas9-Dnmt3a to two CTCF sites to 
investigate whether de novo methylation would interfere with the looping function of CTCF 
(Fig 5B and 5F). Doxycycline-inducible dCas9-Dnmt3a mES cells (Fig S2H) were infected 
with lentiviruses expressing the gRNAs and transduced cells were FACS sorted for 
subsequent analysis.
Targeting of dCas9-Dnmt3a to the CTCF binding site bordering the miR290 loop that 
harbors a super-enhancer (Fig 5B) induced de novo methylation of CpGs at this site (Fig 5D 
and 5E). Gene expression analysis of transduced cells showed a significant elevation of 
Nlrp12 gene, which is outside of this super-enhancer-containing insulated neighborhood and 
next to the targeted CTCF site, but did not affect the expression of genes that are located 
inside the miR290 loop or of genes in other neighboring loops including AU01801 and 
Myadm (Fig 5C). Similarly, targeting of dCas9-Dnmt3a to the CTCF binding site bordering 
the Pou5f1 gene loop that harbors another super-enhancer (Fig 5F) induced methylation of 
CpGs in the CTCF binding sequence (Fig 5H and 5I), and increased the expression of 
H2Q10, which is located in a neighboring loop and next to the targeted CTCF site, but did 
not affect the expression of Pou5f1 gene itself or Tcf19 gene in the other neighboring loop 
(Fig 5G). For either targeted CTCF sites, a catalytically inactive Dnmt3a form (dC-dD) did 
not induce changes in methylation level or gene expression as did by dC-D (Fig 5C–E, and 
5G–I). These observations are consistent with the results obtained when these CTCF sites 
were deleted (Dowen et al., 2014), and support the notion that methylation of the CTCF 
binding site interferes with its insulator function.
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To test whether targeted methylations of CTCF binding sites would result in increased 
interaction frequencies between insulated super-enhancers and activated genes, 
Chromosome Conformation Capture (3C) assay was performed at these loci. As shown in 
Fig 6A, the interaction frequency between super-enhancers in the miR290 loop and the 
newly activated gene (Nlrp12) in the neighboring loop was significantly increased but the 
interaction between Nlrp12 and Myadm genes remained the same, indicating an open 
conformation for this targeted CTCF loop. To confirm that the increased interaction 
frequency was due to blocking CTCF anchoring, we performed a CTCF ChIP assay. Binding 
of CTCF to the targeted genomic site was significantly reduced in the sample with miR290 
target gRNAs as compared to the sample with a scrambled gRNA, gRNAs targeting other 
CTCF binding sites or a catalytically inactive dC-dD with miR290 target gRNAs (Fig 6B), 
supporting the notion that DNA methylation blocks CTCF anchoring and thus alters the 
CTCF loop conformation. A similar set of experiments was performed for the second CTCF 
loop (Pou5f1 loop) demonstrating increased interaction frequency between the insulated 
super-enhancers and the newly activated gene (H2Q10), and decreased binding of CTCF 
after targeted methylation of its binding site (Fig 6C and 6D).
In summary, our results demonstrate that the dCas9-Dnmt3a system can be used to change 
the methylation state of specific CTCF anchor sites and thus to interfere with the CTCF 
looping function.
In vivo demethylation of an endogenous locus for gene activation by dCas9-Tet1
To test whether the dCas9-mediated DNA methylation-editing tools could be used to alter 
methylation in vivo we utilized a methylation sensitive reporter mouse previously generated 
(Fig 7A, Stelzer et al, Cell Reports, 2016, in press). In these transgenic mice, a methylation 
sensitive Snrpn-GFP cassette was inserted into the Dlk1-Dio3 locus to report the 
methylation status of its intergenic-differentially methylated region (IG-DMR). As the IG-
DMR of this locus acquires paternal methylation during spermatogenesis, the GFP reporter 
(IG-DMRGFP/Pat) is constitutively repressed in heterozygous mice carrying the paternal 
Snrpn-GFP allele (Stelzer et al., Cell Reports, 2016, in press). As shown above the GFP 
reporter in the Dazl locus was activated by targeted promoter demethylation in mES cells 
(Fig 1). To assess whether the Dlk1-Dio3 locus GFP reporter could be activated by dCas9-
Tet1 in differentiated cells we derived adult mouse skin fibroblast cells from the tails of IG-
DMRGFP/Pat transgenic mice, which were then transduced by lentiviruses expressing dCas9-
Tet1 with Snrpn target gRNAs or a scrambled gRNA, or a catalytically dead form of Tet1 
(dC-dT) with Snrpn target gRNAs (Fig 7A). The results in Fig 7B and 7C reveal GFP 
reporter activation in about 80% of Cherry (gRNA) positive fibroblasts but only when 
transduced by both dCas9-Tet1 and Snrpn gRNAs lentiviruses. FACS analysis of these cells 
further confirmed this notion (Fig S7A–C).
To investigate whether the DNA methylation status can be modified in vivo, we infected 3 
epidermal sites on the ventral side of an IG-DMRGFP/Pat transgenic mouse with the dCas9-
Tet1 and Snrpn gRNAs (Fig S7D). Cells were sparsely infected with cherry expression seen 
only in some of the hair follicles. dCas9-Tet1 with Snrpn gRNAs, but not dCas9-Tet1 with 
the scrambled gRNA or dC-dT with Snrpn gRNAs, was able to activate GFP reporter 
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expression in about 85% infected skin dermal cells in vivo (Fig 7H, S7E&F). In addition we 
infected the brain of an IG-DMRGFP/Pat transgenic mouse with lentiviral vectors using a 
stereotaxic setup and analyzed the effect on targeted DNA methylation in brain slices by 
confocal microscopy. To eliminate possible inter-individual variability, we injected lentiviral 
vectors expressing dCas9-Tet1 and Snrpn gRNAs, as well as the two negative control vector 
combinations into different regions of the same brain (Fig 7D). As shown in Fig 7E&F, after 
infection with all three lentiviral combinations as indicated by Cherry expression, only 
lentiviral vectors expressing dCas9-Tet1 with Snrpn gRNAs, but not vectors expressing 
dCas9-Tet1 with sc gRNA or dC-dT with Snrpn gRNAs, activated the GFP reporter with an 
activation efficiency of about 70% (Fig 7G).
DISCUSSION
In this study we have repurposed the CRISPR/Cas9 system to edit the methylation status of 
genomic sequences. The catalytically inactive Cas9 protein (dCas9) was fused either to the 
catalytic domain of Tet1 (dCas9-Tet1) or to Dnmt3a (dCas9-Dnmt3a) to predictably alter the 
epigenetic state of target sequences. A GFP reporter inserted into the promoter region of the 
methylated and silenced Dazl gene was demethylated and activated when targeted by dCas9-
Tet1 whereas the GFP reporter inserted into the promoter region of the active and 
unmethylated Gapdh gene was de novo methylated and silenced when targeted by dCas9-
Dnmt3a. When the dCas9-Tet1 was targeted to the inactive BDNF promoter IV in post-
mitotic neurons, the promoter became demethylated and activated. Importantly, this tool 
predictably altered the methylation state and activity of regulatory regions: Targeted 
demethylation of the inactive distal enhancer of MyoD activated the gene and facilitated 
muscle differentiation and targeted methylation of CTCF anchor sites inhibited CTCF 
binding and interfered with its function as an insulator between chromatin loops. Finally, the 
editing tools can in vivo alter the methylation state of regulatory sequences as injection of 
the lentiviral vectors of dCas9-Tet1 with target gRNAs into the dermis or brain of transgenic 
mice demethylated the methylated Snrpn promoter in the Dlk1-Dio3 imprinted locus and 
activated the methylation-sensing GFP reporter.
Dynamic DNA methylation has been proposed to decode neuronal activities (Sweatt, 2013). 
For instance, treatment of neurons with KCl has been shown to de-silence promoter IV of 
BDNF and induce BDNF expression associated with demethylation of some methylated 
CpGs in the promoter region (Chen et al., 2003; Martinowich et al., 2003). When the BDNF 
promoter IV was targeted by dCas9-Tet1, extensive demethylation of methylated CpGs was 
observed, and BDNF was activated to a similar level as when the cultures were treated with 
KCl. Because the neurons were post-mitotic, the dCas9-Tet1-mediated demethylation of the 
promoter sequences was likely the result of active demethylation as has been proposed 
previously (Wu and Zhang, 2014). Although it is possible that some CpGs in the BDNF 
promoter were 5-fC/5-caC modified after targeting with dCas9-Tet1/gRNA, blocking 
restoration of 5-fC/5-caC into unmethylated cytosine by inhibition of the BER pathway 
reduced BDNF expression, suggesting that demethylation of the BDNF promoter IV 
contributes to the activation of BDNF. Importantly, our results establish a causal relationship 
between demethylation of BDNF promoter IV and gene activation.
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The role of DNA methylation as a barrier between cell lineages is consistent with the 
previous observation that demethylation of DNA in fibroblasts by treatment with 5-Aza can 
activate MyoD and mediate myotube formation (Constantinides et al., 1977). Targeting of 
dCas9-Tet1 to the methylated distal enhancer of MyoD in fibroblasts induced demethylation 
of CpGs and resulted in a moderate activation of MyoD but failed to generate myoblasts. 
However, when dCas9-Tet1/gRNA lentiviral transduction was combined with 5-Aza 
treatment, a significantly enhanced myoblast and myotube formation was observed as 
compared to 5-Aza treatment alone. It is possible that demethylation of the additional DMRs 
in combination with the distal enhancer may be required to induce efficient conversion of 
fibroblasts to myoblasts.
Recent studies of mammalian chromosome structure reveal that chromatin is organized in 
topologically associating domains and gene loops mediated by chromatin architecture 
proteins such as Cohesin and CTCF (Dekker and Mirny, 2016). Emerging data suggest that 
higher-order chromatin structures confer epigenetic information during development and are 
frequently altered in cancer (Ji et al., 2016; Narendra et al., 2015). It has been reported that 
binding of CTCF is inhibited when its recognition sequence is methylated (Bell and 
Felsenfeld, 2000; Wang et al., 2012). Targeting of dCas9-Dnmt3a to two CTCF binding sites 
induced de novo methylation of CpGs in these sites and interfered with the insulator 
function of the protein as evidenced by increased interaction frequencies between insulated 
super-enhancers in the targeted loop and genes in the neighboring loop causing up-
regulation of these genes. This suggests that the dCas9-Dnmt3a system is a useful tool to 
manipulate chromatin structure and to assess its functional significance during development 
and in disease context.
Our results indicate that dCas9 fused to the epigenetic effectors Tet1 and Dnmt3a represent a 
powerful toolbox to edit DNA methylation of specific genomic sequences. Comparison of 
these tools with TALE-based method showed a higher efficacy and resolution for 
methylation editing, and dCas9 ChIP-seq followed by bisulfite sequencing of potential off-
target binding loci revealed marginal changes in methylation levels, suggesting that high 
specificity can be achieved with properly designed gRNAs. During the preparation of our 
manuscript, Vojta et al. also reported that dCas9 fused with Dnmt3a can be used to 
methylate two human gene promoters (Vojta et al., 2016), and Xu et al. and Choudhury et al. 
reported that dCas9 fused with Tet1 can be used to demethylate gene promoters (Choudhury 
et al., 2016; Xu et al., 2016). Therefore, these dCas9-Dnmt3a/Tet1 tools will be useful to 
gain insight into the functional significance of DNA methylation in diverse biological 
processes such as gene expression, cell fate determination, and organization of high-order 
chromatin structures.
Methods and Resources (6 sub-sections)
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the 
corresponding author Rudolf Jaenisch (jaenisch@wi.mit.edu)
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse lines and breeding strategies—Tet1 mutant mice were previously generated in 
our lab (Dawlaty et al., 2011). Tet1 KO mice in the study were maintained in a mixed 129 
and C57BL/6 background. To obtain Tet1 KO mice, male and female mice heterozygous for 
Tet1 were crossed. To obtain wild type mouse primary cortical neurons, male and female 
C57BL/6 mice were mated. IG-DMRGFP/Pat methylation reporter mouse line was generated 
as described (Ref: Stelzer et al., Parent-of-origin DNA methylation dynamics during mouse 
development, Cell Report, in press). Male mice with IG-DMRGFP/Pat reporter allele were 
crossed with C57BL/6 females to generate adult offsprings carrying the paternally 
transmitted allele for in vivo DNA methylation editing analysis. Mice were handled in 
accordance with institutional guidelines and approved by the Committee on Animal Care 
(CAC) and Department of Comparative Medicine (DCM) of Massachusetts Institute of 
Technology.
Mouse primary cortical neuron culture, EDU labeling and neural induction—
Dissociated E17.5 cortical neuron cultures were generated from wild type or Tet1 KO mouse 
embryos as described previously (Ebert et al., 2013). Briefly, E17.5 cortices were dissected 
in ice-cold 1 X HBSS (Gibco 14185-052) containing 1 x pen/strep (Gibco: 15140122), 1 x 
pyruvate (Gibco: 11360070) and 30 mM Glucose. Tissues were minced into around 1 mm3 
and dissociated with Papain neural tissue dissociation system (Worthington Biochemicals) 
following the manufacturer’s instruction. Cells were resuspended in NM5 media (%5 FBS 
(Hyclone), 2% B27 supplement (Gibco 17504044), 1 x pen/strep and 1 x glutamax I (Gibco 
35050-061)). 1 x 106 cells were plated per well of a 6-well plate coated with poly-D-lysine 
(PDL, Sigma). On DIV2, cells were treated with 2.5 uM AraC overnight (Sigma C-6645) to 
eliminate the excessive cell division of mitotic astrocytes and neural progenitor cells. 
Cultures were fed at DIV3 with fresh NM5 media and subsequently membrane depolarized 
with 50 mM KCl or infected with preferred lentivirus. We started the treatment at the very 
beginning of the in vitro culture so the step of AP5 and TTX (tetrodotoxin) treatment to 
silence basal activity in the culture before KCl treatment was omitted. For EDU labeling, 
primary neuronal culture were treated with EDU at a final concentration of 10 uM for 24 
hours followed by Click-it EDU labeling procedure according to the manufacturer’s 
instruction (Thermo Fisher Scientific). Cells were fixed for immunohistochemical analysis, 
lysed in Trizol to extract total RNA for RT-qPCR or lysed to extract DNA for bisulfite 
sequencing analysis.
METHOD DETAILS
Plasmid design and construction—PCR amplified Tet1 catalytic domain from 
pJFA344C7 (Addgene plasmid: 49236), Tet1 inactive catalytic domain from MLM3739 
(Addgene plasmid: 49959), or Dnmt3a from pcDNA3-hDNMT3A (Addgene plasmid: 
35521) were cloned in modified pdCas9 plasmid (Addgene plasmid: 44246) with BamHI 
and EcoRI sites. Then dCas9-NLS-Tet1 or dCas9-NLS-Dnmt3a were PCR amplified and 
cloned into FUW vector (Addgene plasmid: 14882) with AscI and EcoRI to package 
lentiviruses. NLS-dCas9-NLS-Tet1 was cloned by inserting annealed oligos (NLS) into 
FUW-dCas9-NLS-Tet1 with XbaI and AscI. The gRNA expression plasmids were cloned by 
inserting annealed oligos into modified pgRNA plasmid (Addgene plasmid: 44248) with 
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AarI site. The PiaggyBac-dCas9-Tet1 and -dCas9-Dnmt3a were cloned by ligation of PCR-
amplified dCas9-NLS-Tet1 or dCas9-NLS-Dnmt3a from FUW constructs with modified 
PiggyBac transposon vector (Wilson et al., 2007) with NheI and EcoRI. All constructs were 
sequenced before transfection. Primer information for gRNA design and construction is 
listed in Supplemental Table S2. Related plasmids have been deposited into Addgene 
plasmid database. TALE-Dnmt3a construct targeting p16 locus is a gift from Dr. Klaus 
Kaestner, and TALE-Tet1 targeting RHOXF2 locus is from Addgene (Plasmid #49943). Full 
length protein sequences of dCas9-Dnmt3a and dCas9-Tet1CD and their mutants are listed 
in Supplemental Table S6.
Cell culture, lentivirus production, and stable cell line generation—Mouse 
embryonic stem cells (mESCs) were cultured on irradiated mouse embryonic fibroblasts 
(MEFs) with standard ESCs medium: (500 ml) DMEM supplemented with 10% FBS 
(Hyclone), 10 ug recombinant leukemia inhibitory factor (LIF), 0.1 mM β-mercaptoethanol 
(Sigma-Aldrich), penicillin/streptomycin, 1 mM L-glutamine, and 1% nonessential amino 
acids (all from Invitrogen). C3H10T1/2 cells were cultured in standard DEME medium with 
10% FBS. Lentiviruses expressing dCas9-Tet1, dCas9-Dnmt3a, and gRNAs were produced 
by transfecting HEK293T cells with FUW constructs or pgRNA constructs together with 
standard packaging vectors (pCMV-dR8.74 and pCMV-VSVG) followed by ultra-
centrifugation-based concentration. Virus titer (T) was calculated based on the infection 
efficiency for 293T cells, where T = (P*N) / (V), T = titer (TU/ul), P = % of infection 
positive cells according to the fluorescence marker, N = number of cells at the time of 
transduction, V = total volume of virus used. Note TU stands for transduction unit. To 
generate stable cell lines with integrated Doxycycline-inducible dCas9-Tet1 or dCas9-
Dnmt3a transgenes, PiggyBac-dCas9-Tet1 or -dCas9-Dnmt3a construct, with a helper 
plasmid expressing transposase, were transfected into C3H10T1/2 cell using X-tremeGENE 
9 transfection reagent (Roche) or into mESCs cells using Xfect transfection reagent 
(Clontech), according to the provider’s protocol. Stably integrated cells were selected with 
G418 (400 ug/ml) for 10 days. Adult mouse fibroblasts were derived from tails of IG-
DMRGFP/Pat reporter mice. Briefly, ~ 2 cm-long mouse tail was obtained from 3 month old 
mouse carrying paternally transmitted IG-DMR-Snrpn-GFP methylation reporter, and 
sterilized by 70% EtOH. ~ 2 mm x 2 mm minced tail pieces were digested with 5 ml of 
1mg/ml Collagenase IV at 37°C for 90 min in a 15 ml Falcon tube. 5 ml MEF medium were 
added into the tube to terminate the digestion. Dissociated cells were extruded through a 40 
um cell strainer with gentle grind using a syringe plug. Cells were then collected and 
cultured for viral infection. Cells were analyzed 3 days post-infection in this study.
Viral infection of mice and tissue sample preparation—Mice were infected with 
appropriate lentiviral cocktails in accordance with institutional guidelines and approved by 
the Committee on Animal Care (CAC) and Department of Comparative Medicine (DCM) of 
Massachusetts Institute of Technology. Specifically, to infect mouse skin, lentiviruses 
expressing dCas9-Tet1 with sc gRNA, an inactive mutant of dC-dT with target gRNAs, and 
dCas9-Tet1 with target gRNAs were delivered by Hamilton syringe into multiple dermal 
sites on the ventral side of the deeply anesthetized mouse carrying the Paternal IG-DMRGFP 
reporter allele (Fig S7D). To infect mouse brain, various lentiviral mixtures were delivered 
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by stereotaxic setup (Leica BIOSYSTEMS, BenchMark Digital Stereotaxic with Manual 
Fine Drive) into the following locations (relative to the Franklin and Paxinos mouse brain 
atlas) of the deeply anesthetized mouse carrying the paternal IG-DMRGFP/Pat reporter allele 
(Fig 7D): dCas9-Tet1 with sc gRNA (A-P 0.70mm, M-L 1.50mm, D-V 1.50mm), an inactive 
mutant of dC-dT with Snrpn gRNAs (A-P −1.90mm, M-L −1.50mm, D-V 1.50mm), and 
dCas9-Tet1 with Snrpn gRNAs (A-P −1.90mm, M-L 1.50mm, D-V 1.50mm). The titers for 
dC-T/dC-dT and gRNA lentiviruses are 1.2 x 104 TU/ul and 1.2 x 105 TU/ul respectively. 
Mice were sacrificed 3 days after infection. The animals were fixed by transcardial perfusion 
with 4% paraformaldehyde (PFA)/PBS. Fixed skin pads and brain samples were dissected 
and post fixed with 4% paraformaldehyde (PFA)/PBS overnight at 4 °C. The brain samples 
were sectioned with a vibratome (Leica VT1100) at 150 um thickness and the skin samples 
were sectioned with a cryostat (Leica) at 10 um thickness followed by immunohistochemical 
analysis. For vibratome sectioning, tissues were embedded in 3% agarose gel. For 
cryosectioning, tissues were equilibrated in 30% sucrose/PBS prior to embedding in Optimal 
Cutting Temperature (OCT) compound.
Immunohistochemistry, microscopy, and image analysis—Neurons, HEK293T 
cells, mouse ES cells and C3H10T1/2 cells were fixed with 4% paraformaldehyde (PFA) for 
10 min at room temperature. Cells were permeablized with PBST (1 x PBS solution with 
0.1% Triton X-100) before blocking with 10% Normal Donkey Serum (NDS) in PBST. 
Cells were then incubated with appropriately diluted primary antibodies in PBST with 5% 
NDS for 1 hours at room temperature or 12 hours at 4 °C, washed with PBST for 3 times at 
room temperature and then incubated with desired secondary antibodies in TBST with 5% 
NDS and DAPI to counter stain the nuclei. Cells were washed 3 times with PBST before 
mounted onto slides with Fluoromount G (SouthernBiotech). Immunostaining procedures 
for tissue sections were previously described (Wu et al., 2014a). Briefly, sections were 
permeablized with PBST (1 x PBS solution with 0.5% Triton X-100) for 1 hour at RT before 
blocking with 10% Normal Donkey Serum (NDS) in PBST. Slices were then incubated with 
desired primary antibodies in PBST with 5% NDS for 24 hours at 4 °C, washed with PBST 
for 3 times at room temperature and then incubated with secondary antibodies in TBST with 
5% NDS and DAPI to counter stain the nuclei. Sections were washed 3 times with PBST 
before slide mounting. The following antibodies were used in this study: Chicken anti-GFP 
(1:1000, Aves Labs), Mouse anti-Cas9 (7A9, 1:1000, Active Motif), Rabbit anti-BDNF 
(1:1000, Thermo Fisher), Chicken anti-MAP2 (1:1000, Encor Biotech), Mouse anti-MAP2 
(1:1000, Sigma-Aldrich), Mouse anti-Tuj1 (1:1000, Biolegend), Rabbit anti-MyoD (C-20, 
1:1000, Santa Cruz Biotechnology), Mouse anti-MHC (MF20, 1:1000, R&D systems), 
Mouse anti-MyoG (F5G, 1:1000, Thermo Fisher). Images were captured on a Zeiss LSM710 
confocal microscope and processed with Zen software, ImageJ/Fiji, and Adobe Photoshop. 
For imaging based quantification, unless otherwise specified, 3–5 representative images 
were quantified and data were plotted as mean ± SD with Excel or Graphpad.
FACS analysis—To assess the proportion of GFP and/or Cherry positive cells after 
treatment, the treated cells were dissociated with trypsin and single-cell suspensions were 
prepared in growth medium subject to a BD FACSAria cell sorter according to the 
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manufacture’s protocol at the Whitehead Institute Flow Cytometry Core. Data were 
analyzed with FlowJo software.
Fibroblast-to-myoblast conversion assay—Myoblast conversion assay was described 
previously (Constantinides et al., 1977). Briefly, C3H10T1/2 mouse embryonic fibroblast 
cells were plated as 1 x 104 cells per well in 6-well plate, and then infected with lentiviruses 
expressing dCas9-Tet1 and target gRNAs. 24-hour post infection, cells were treated with 
vehicle control (HEPES buffer) or 5-Azacytidine (1 uM) for 24-hour, and harvested at 
different time points for subsequently analysis. DMRs upstream of mouse MyoD gene were 
defined based on human/mouse genome homology (Schultz et al., 2015).
Western blot—HEK293T cells were transfected with various constructs by X-tremeGENE 
9 reagent following manufacturer’s protocol. 2-day post transfection, cells were lysed by 
RIPA buffer with proteinase inhibitor (Invitrogen), and subject to standard immunoblotting 
analysis. Mouse anti-Cas9 (1:1000, Active Motif) and mouse α-Tubulin (1:1000, Sigma) 
antibodies were used.
RT-qPCR—Cells were harvested using Trizol followed by Direct-zol (Zymo Research), 
according to manufacturer’s instructions. RNA was converted to cDNA using First-strand 
cDNA synthesis (Invitrogen SuperScript III). Quantitative PCR reactions were prepared with 
SYBR Green (Invitrogen), and performed in 7900HT Fast ABI instrument. Primer 
information for RT-qPCR is listed in Supplemental Table S3.
ChIP assay—ChIP experiment was performed as previously described (Dowen et al., 
2014). Briefly, cells were cross-linked by 1% formaldehyde in the medium for 10 min in 
room temperature, and then quenched by adding 0.125 M Glycine for 5 min. Collected cells 
were washed with PBS twice, and then re-suspended in 3.5 ml of sonication buffer. 
Sonication was performed for 10 cycles with 0.5 min pulse on and 1 min rest, and 24 watts 
in ice-water mixture. Then cell lysate was spun down with 14,000 x rpm for 10 min at 4 °C. 
50 ul of supernatant was saved as input for gDNA. 10 ul of anti-CTCF antibody (EMD 
Millipore: 07729) or anti-Cas9 antibody (Active Motif) was added and incubate overnight at 
4 °C. 50 ul protein G dynabeads was added into antibody-cell lysate mixture and incubate 
overnight at 4 °C. Then beads were washed with sonication buffer, sonication buffer with 
high salt (500 mM NaCl), LiCl wash buffer, and TE buffer. Bound protein-DNA complex 
was eluted from beads by incubation in a 65 °C oven for 15 min, and then reverse cross-
linked under 65 °C over-night. The bound DNA was purified with Qiagen QIAquick PCR 
Purification Kit, and then subject to qPCR analysis or sequencing.
ChIP-seq data analysis—Sequencing data was analyzed with a previously reported 
method (Wu et al., 2014b). Reads are demultiplexed and the first 25 bases are mapped to 
mouse genome (mm10) using STAR (Dobin et al., 2013), requiring unique mapping 
allowing one mismatch. Mapped reads are collapsed and the same number of reads (about 
15 million) are randomly sampled from each sample to match sequencing depth. Peaks are 
called using MACS (Zhang et al., 2008) with default settings. For each sample, the other five 
samples are each used as a control and only peaks called over all five controls are defined as 
candidate peaks. Candidate peaks are filtered by fold of enrichment over background and the 
Liu et al. Page 15
Cell. Author manuscript; available in PMC 2017 September 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
threshold is chosen such that no peaks pass this threshold in the four control samples (input, 
mock IP, dCas9 alone, and scrambled gRNA). Note that six candidate peaks in input mapped 
to 45S rRNA and mitochondria DNA are excluded from the analysis. Raw data is available 
in the following link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=ktohskmgnhudhud&acc=GSE83890
Bisulfite Conversion, PCR and Sequencing—Bisulfite conversion of DNA was 
established using the EpiTect Bisulfite Kit (Qiagen) following the manufacturer’s 
instructions. The resulting modified DNA was amplified by first round of nested PCR, 
following a second round using loci specific PCR primers (Supplemental Table S3). The first 
round of nested PCR was done as follows: 94 °C for 4 min; 55 °C for 2 min; 72 °C for 2 
min; Repeat steps 1–3 1 X; 94 °C for 1 min; 55 °C for 2 min; 72 °C for 2 min; Repeat steps 
5–7 35X; 72 °C for 5 min; Hold 12 °C. The second round of PCR was as follows: 95 °C for 
4 min; 94 °C for 1 min; 55 °C for 2 min; 72 °C for 2 min; Repeat steps 2–4 35 X; 72 °C for 
5 min; Hold 12°C. The resulting amplified products were gel-purified, sub-cloned into a 
pCR2.1-TOPO-TA cloning vector (Life technologies), and sequenced. Primer information 
for bisulfite sequencing is listed in Supplemental Table S4.
Locus-specific TAB-seq—TAB-Seq was performed as described previously (Yu et al., 
2012). Briefly, 1 ug of genomic DNA from treated mouse cortical neuron was glucosylated 
in a solution containing 50 mM HEPES buffer (pH 8.0), 25 mM MgCl2, 100 ng/ml model 
DNA, 200 mM UDP-Glc, and 1 mM bGT at 37C for 1 hr. After the reaction, the DNA was 
column purified. The oxidation reactions were performed in a solution containing 50 mM 
HEPES buffer (pH 8.0), 100 mM ammonium iron (II) sulfate, 1 mM a-ketoglutarate, 2 mM 
ascorbic acid, 2.5 mM DTT, 100 mM NaCl, 1.2 mM ATP, 15 ng/ml glucosylated DNA, and 
3 mM recombinant mTet1. The reactions were incubated at 37C for 1 hr. After proteinase K 
treatment, the DNA was column purified and then applied to EpiTect Bisulfite Kit 
(QIAGEN) following the supplier’s instruction. The resulting modified DNA was amplified 
by first round of nested PCR, following a second round using loci specific PCR primers 
(Supplemental Table S3). The resulting amplified products were gel-purified, sub-cloned 
into a pJET cloning vector (Life technologies), and sequenced. Primer information for 
bisulfite sequencing is listed in Supplemental Table S4.
Chromosome Conformation Capture (3C) assay—5 x 106 mESCs were fixed with 
1% formaldehyde for 20 min at room temperature, and the reaction was quenched by 0.125 
M glycine for 5 min at room temperature. Cross-linked cells were collected and washed with 
1 ml ice cold PBS. Cell pellet was re-suspended with 550 µl lysis buffer (10 mM Tris-HCl 
with pH 8.0, 10 mM NaCl, and 0.2% IGEPAL CA630 with proteinase inhibitor), and 
incubated on ice for 20 min. Cell pellet was then washed twice with 1 x NEB buffer 2 (NEB, 
B7002S), then incubated with 50 µl 0.5% SDS for 10 min at 62 °C. After heating, 145 µl 
H2O and 25 µl 10% Triton X-100 were added into the mixture and incubate for 15 min at 
37 °C. 25 µl 10 x NEB buffer 2 and 100 U BglII (NEB, R0144S) were added to digest 
chromatin over night at 37 °C. The digest reaction was inactivated by incubation for 20 min 
at 62 °C. Then 713 µl H2O, 120 µl 10 x T4 DNA ligase buffer (NEB, B0202), 100 µl 10% 
Triton X-100, 12 µl 10 mg/ml BSA, and 5 µl T4 DNA ligase (NEB, M0202) were added and 
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incubated for 22 hour at 16 °C. The chromatin was reverse cross-linked, and DNA was 
purified by phenol:chloroform:isoamyl alcohol (Sigma, P3803) extraction. The 3C 
interactions at the miR290 and Pou5f1 loci (Fig 6A and 6C) were analyzed by quantitative 
real-time PCR using custom Taqman probes. The amount of DNA in the qPCR reactions 
was normalized across 3C libraries using a custom Taqman probe directed against the Actb 
locus. Primer and probe sequences are listed in Supplemental Table 5.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact value of n, the definition of center, dispersion and 
precision measures (mean ± SEM) and statistical significance are reported in the Figures and 
the Figure Legends. Data is judged to be statistically significant when p < 0.05 by two-tailed 
Student’s T-Test or 2-way ANOVA, where appropriate.
DATA AND SOFTWARE AVAILABILITY
Raw data files for the ChIP-seq analysis have been deposited in the NCBI Gene Expression 
Omnibus under accession number GSE83890.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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highlights
dCas9-Tet1 and -Dnmt3a enable precise editing of CpG methylation in vitro 
and in vivo
Targeted demethylation of BDNF promoter IV activates BDNF in neurons
Targeted enhancer demethylation facilitates MyoD-induced muscle cell 
reprogramming
Targeted de novo methylation of CTCF motifs alters CTCF-mediated 
chromatin loops
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In brief
DNA methylation patterns can be specifically altered in mammalian cells using CRISPR/
Cas9-based approaches.
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Figure 1. 
Activation of the Dazl-Snrpn-GFP reporter by dCas9-Tet1.
(A) Upper panel: schematic representation of a catalytic inactive mutant Cas9 (dCas9) fused 
with Tet1 for erasing DNA methylation, and with Dnmt3a for de novo methylation of 
specific sequences. Lower panel: an optimized dCas9-effector construct and a guide RNA 
construct with puro and Cherry cassettes.
(B) Schematic representation of targeting the Snrpn promoter region by dCas9-Tet1 with 
specific gRNAs to erase methylation and activate GFP expression.
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(C) Dazl-Snrpn-GFP mESCs were infected with lentiviruses expressing dCas9-Tet1 (dC-T) 
with a scrambled gRNA (sc gRNA) or 4 gRNAs targeting the Snrpn promoter region (target 
gRNA). Percentage of GFP positive cells were calculated by flow cytometric analysis of 
these cells 3-day post infection, and shown as the mean percentages of GFP positive cells ± 
SD of two biological replicates. Note that the percentages of GFP-positive cells are 
expressed as the fraction of infected Cherry-positive cells.
(D) Left, representative fluorescence images of the sorted Cherry positive cells in C after 
culturing for 1 week. Scale bar: 250 um. Right, percentages of GFP positive colonies were 
quantified, and shown as the mean percentages of GFP positive cells ± SD of two biological 
replicates.
(E) Bisulfite sequencing of cells described in C.
(F) Methylation levels of individual CpGs in the Snrpn promoter region and the adjacent 
Dazl locus. Shown is the mean percentage ± SD of two biological replicates. See also Figure 
S1 and S2.
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Figure 2. 
Silencing of the Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a.
(A) Schematic representation of targeting the Snrpn promoter region by dCas9-Dnmt3a with 
specific gRNAs to methylate the promoter and silence GFP expression.
(B) Gapdh-Snrpn-GFP mESCs were infected with lentiviruses expressing dCas9-Dnmt3a 
(dC-D) with a scrambled gRNA (sc gRNA) or gRNAs targeting the Snrpn promoter region 
(target gRNA). Percentage of GFP negative cells was calculated by flow cytometric analysis 
3-days after infection, and is shown as the mean percentages of GFP negative cells ± SD of 
two biological replicates. Note that the percentages of GFP-positive cells are expressed as 
the fraction of infected Cherry-positive cells.
(C) Left, representative fluorescence images of the sorted Cherry-positive cells in B after 
culturing for 1 week. Scale bar: 250 um. Right, percentages of GFP negative colonies were 
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quantified, and are shown as the mean percentages of GFP negative cells ± SD of two 
biological replicates.
(D) Bisulfite sequencing of cells described in B.
(E) Methylation levels of individual CpGs in the Snrpn promoter region and the adjacent 
Gapdh locus. Shown is the mean percentage ± SD of two biological replicates.
(F) Gapdh-Snrpn-GFP mESCs with Doxycycline-inducible dCas9-Dnmt3a were infected 
with lentiviruses expressing gRNAs targeting the Snrpn promoter region in the presence of 
Doxycycline (2 ug/ml). Percentages of GFP negative cells were calculated by flow 
cytometric analysis 3-day after infection, and are shown as the mean percentages of GFP 
negative cells ± SD of two biological replicates. Note that the percentages of GFP-positive 
cells are expressed as the fraction of infected Cherry-positive cells.
(G) Left, representative fluorescence images of the sorted Cherry-positive population in F 
after culturing for 1 week with or without Doxycycline. Scale bar: 250 um. Right, 
percentages of GFP negative colonies were quantified, and are shown as the mean 
percentages of GFP negative cells ± SD of two biological replicates.
(H) Methylation level of each individual CpG in the Snrpn promoter region and the adjacent 
Gapdh locus from cells in G. Shown is the mean percentage ± SD of two biological 
replicates. See also Figure S2.
Liu et al. Page 26
Cell. Author manuscript; available in PMC 2017 September 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Targeted demethylation of BDNF promoter IV by dCas9-Tet1 to activate BDNF in neurons.
(A) Schematic representation of targeting BDNF promoter IV by dCas9-Tet1 (dC-T) with 
specific gRNAs to erase methylation and activate BDNF expression.
(B) Mouse cortical neurons cultured in vitro for 3 days (DIV3) were infected with 
lentiviruses expressing dC-T with or without gRNAs targeting the BDNF promoter IV, or a 
catalytic dead form of Tet1 (dC-dT) with BDNF gRNAs for 2 days, and then treated with or 
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without KCl (50 mM) for 6 hours before harvesting for RT-qPCR analysis. Bars are mean ± 
SD of three biological replicates.
(C) Representative confocal images for BDNF induction in B. Stained in red for MAP2 (top 
two panels) or Cherry (bottom two panels), green for BDNF, blue for DAPI and grey for 
dCas9. Scale bar: 50 um.
(D) Bisulfite sequencing of neurons in C.
(E) Methylation levels of each individual CpGs in the BDNF promoter IV region. Shown is 
the mean percentage ± SD of two biological replicates.
See also Figure S4.
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Figure 4. 
Targeted demethylation of the MyoD distal enhancer by dCas9-Tet1 to facilitate conversion 
of fibroblasts to myoblasts.
(A) Schematic representation of targeting the MyoD distal enhancer (DE) region in DMR-5 
by dCas9-Tet1 (dC-T) with specific gRNAs.
(B) C3H10T1/2 cells were infected with lentiviruses expressing dC-T with target gRNAs, or 
a catalytic dead form of Tet1 (dC-dT) with target gRNAs for 2 days. Cherry positive cells 
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were FACS sorted for RT-qPCR analysis. Bars represent mean ± SD of three experimental 
replicates.
(C) Bisulfite sequencing of cells in B.
(D) Methylation level of individual CpGs in the MyoD DE region. Shown is the mean 
percentage ± SD of two biological replicates.
(E) Representative confocal images for C3H10T1/2 cells on day 14 in the fibroblast-to-
myoblast conversion assay. Stained in green for MyoD, magenta for MHC and blue for 
DAPI. Scale bar: 200 um.
(F) Quantification of MyoD positive cell ratio 14-day post infection with lentiviruses 
expressing dC-T alone, dC-T or dC-dT with gRNAs targeting DMR-5.
(G) Distribution profile of MHC positive cell clusters based on nuclei number per MHC+ 
cluster (grouped as 2–5, 6–10, 11–20 and >20 nuclei per MHC+ cluster) 14-days post 
infection.
(H) Quantification of myotube density in MHC positive clusters with more than 2 or 5 nuclei 
at 14-days after infection. Data are quantified from 3–5 representative images for F-H. Bars 
represent mean ± SD.
See also Figure S5.
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Figure 5. 
Targeted methylation of CTCF binding sites.
(A) Schematic representation of targeting the CTCF binding site by dCas9-Dnmt3a with 
specific gRNAs to induce de novo methylation, blocking CTCF recruitment, and opening 
CTCF loops which alters gene expression in the adjacent loop.
(B) Schematic representation of CTCF target-1 (miR290 locus) with super-enhancer and 
miR290 in the loop, AU018091 gene in the left neighboring loop, and Nlrp12 gene in the 
right neighboring loop (close to the targeted CTCF binding site). The Myadm gene is in the 
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adjacent loop right to the loop containing Nlrp12. The super-enhancer domain is indicated as 
a red bar. The targeted CTCF site is highlighted with a box. ChIP-seq binding profiles (reads 
per million per base pair) for CTCF in black and H3K27Ac (super-enhancer) in red, and 
methylation track in yellow with DMR in blue are also shown.
(C–E) Doxycycline-inducible dCas9-Dnmt3a mESCs were infected with lentiviruses 
expressing a scrambled gRNA or CTCF target-1 gRNAs. Cherry-positive cells were FACS 
sorted, cultured in the presence of Doxycycline, and then harvested for RT-qPCR analysis in 
C, for bisulfite-sequencing analysis in D&E. Bars represent mean ± SD of three 
experimental replicates.
(F) Schematic representation of CTCF target-2 with super-enhancer and Pou5f1 gene in this 
loop as in B.
(G–I) The same set of experiments were performed as described in C-E for CTCF target-2, 
and cells were harvested for RT-qPCR analysis as in C and for bisulfite sequencing as in D 
and E. Bars represent mean ± SD of three experimental replicates.
See also Figure S6.
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Figure 6. 
Targeted methylation of CTCF binding sites to manipulate CTCF loops.
(A) Quantitative Chromosome Conformation Capture (3C) analysis of cells described in Fig 
5C at the miR290 locus. The super-enhancer domain is indicated as a red bar. The targeted 
CTCF site is highlighted with a box. Arrows indicate the chromosomal positions between 
which the interaction frequency was assayed. Asterisk indicates the 3C anchor site. ChIP-seq 
binding profiles (reads per million base pair) for CTCF in black and H3K27Ac (super-
enhancer) in red, and methylation track in yellow with DMR in blue are also shown. The 
interaction frequencies between the indicated chromosomal positions and the 3C anchor 
sites are displayed as a bar chart (mean ± SD) on the bottom panel. qPCR reactions were run 
in duplicates, and values are normalized against the mean interaction frequency in cells with 
a scrambled gRNA. (p < 0.05 for all three regions; Student’s t test, ns stands for non-
significant, NC stands for negative control.)
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(B) Anti-CTCF ChIP experiment was performed using cells in A followed by quantitative 
PCR analysis. Bars represent mean ± SD of three experimental replicates.
(C) Quantitative Chromosome Conformation Capture (3C) analysis of cells described in Fig 
5G at the Pou5f1 locus as in A.
(D) Anti-CTCF ChIP experiment was performed using cells in C followed by quantitative 
PCR analysis. Bars represent mean ± SD of three experimental replicates.
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Figure 7. 
Targeted ex vivo and in vivo DNA methylation editing by dCas9-Tet1 to activate a silenced 
GFP reporter.
(A) Schematic diagram illustrating the experimental procedure for the ex vivo activation of a 
silenced GFP reporter in mouse fibroblast cells. Mouse tail fibroblast cells were derived 
from a genetically modified mouse line carrying a paternal IG-DMR-Snrpn-GFP allele (IG-
DMRGFP/Pat) in the Dlk1-Dio3 locus. The IG-DMR-Snrpn promoter on the paternal allele is 
hypermethylated so that the GFP reporter is constitutively silenced. The cultured fibroblast 
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cells were infected with lentiviral vectors expressing dCas9-Tet1 and gRNAs to demethylate 
the Snrpn promoter and activate the GFP reporter.
(B) Representative immunohistochemical images of IG-DMRGFP/Pat fibroblasts infected 
with lentiviruses expressing dCas9-Tet1 (dC-T) with a sc gRNA, an inactive form of dCas9-
Tet1 (dC-dT) with Snrpn target gRNA, or dCas9-Tet1 with Snrpn target gRNA. Stained in 
red for Cherry, green for GFP and DAPI for nuclei. Scale bar: 100 um.
(C) Quantification of the percentage of IG-DMRGFP/Pat mouse fibroblast cells with GFP 
activation in Cherry (gRNAs) positive cells. Bars represent mean ± SD of three experimental 
replicates.
(D) Schematic diagram illustrating the experimental procedure for in vivo activation of GFP 
reporter in the IG-DMRGFP/Pat mouse brain. Lentiviral vectors expressing dC-T and sc 
gRNA, dC-dT and Snrpn target gRNAs, and dC-T and Snrpn target gRNAs were delivered 
with stereotaxic microinjection approach. Brains were sliced and analyzed by 
immunohistochemical approaches.
(E) Representative confocal micrographs for the IG-DMRGFP/Pat mouse brains infected with 
dC-T and sc gRNA, dC-dT and Snrpn target gRNAs, and dC-T and Snrpn target gRNAs. 
Only dC-T with the target gRNAs activated the GFP expression. Scale bar: 100 um.
(F) Confocal micrograph of the boxed area in E. Stained in red for Cherry, green for GFP 
and DAPI for nuclei in E and F. Scale bar: 25 um.
(G–H) Quantification of the percentage of IG-DMRGFP/Pat cells with GFP activation in 
Cherry (gRNAs) positive cells in the in vivo lentiviral delivery experiment in the brain (G) 
and in the skin epidemis (H). Bars represent mean ± SD of more than four representative 
images from 2 animals.
See also Figure S7.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-Cas9 (IF staining) Active Motif Cat#61577 (7A9-3A3)
Mouse monoclonal anti-Cas9 (ChIP) Active Motif Cat#61757 (8C1-F10)
Rabbit polyclonal anti-CTCF EMD Millipore Cat#07729
Chicken polyclonal anti-GFP Aves Labs Cat#GFP-1020
Rabbit polyclonal anti-BDNF Thermo Fisher SCIENTIFIC Cat#OSB00017W
Chicken polyclonal anti-MAP2 Encor Biotech Cat# CPCA-MAP2
Mouse monoclonal anti-MAP2 Sigma-Aldrich Cat#M2320
Mouse monoclonal anti-Tuj1 Biolegend Cat#MMS-435P
Rabbit polyclonal anti-MyoD (C-20) Santa Cruz Biotechnology Cat#sc-304
Mouse monoclonal anti-MHC (MF20) R&D systems Cat#MAB4470
Mouse monoclonal anti-MyoG (F5G) Thermo Fisher SCIENTIFIC Cat#MA5-11486
Chemicals
2-Hydroxyglutarate TRC Toronto Research Chemicals Cat#H942596
ABT-888 Selleck Cat#S1004
5-Aza-2’-deoxycytidine Sigma Aldrich Cat#A3656-5MG
Doxycycline hyclate Sigma Aldrich Cat#D9891-100G
Critical Commercial Assays
EpiTect Bisulfite Kit Qiagen Cat#59104
TAB-seq kit Wisegene Cat#K001
DNeasy Blood & Tissue Kit Qiagen Cat#69504
Zymoclean Gel DNA Recovery Kit Zymo Research Cat#D4002
DNA Clean & Concentrator-5 Zymo Research Cat#D4013
X-tremeGENE™ 9 DNA Transfection Reagent Sigma Aldrich Cat#6365809001
Xfect™ mESC Transfection Reagent Clontech Cat#631320
Direct-zol RNA Miniprep Zymo Research Cat#R2050
SuperScript III First-Strand Synthesis SuperMix Life Technologies Cat#18080400
Fast SYBR Green Master Mix Life Technologies Cat#4385618
Papain neural tissue dissociation system Worthington Biochemicals Cat#LK003150
Deposited Data
Raw data files for RNA sequencing NCBI Gene Expression Omnibus GSE83890
Experimental Models: Organisms/Strains
Mouse: C57Bl/6J Jackson Laboratories RRID:IMSR_JAX:000664
Mouse: B6; Tet1 KO mouse Dawlaty et al., 2011 N/A
Mouse: B6; Dlk1-Dio3 IG-DMR-Snrpn-GFP Stelzer et al., 2016 (in press) N/A
Experimental Models: Cell Lines
V6.5 mESC (C57BL/6 x 129S4/SvJae) Brambrink et al., 2006 N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Dazl-Snrpn-GFP V6.5 mESC Stelzer et al., 2015 N/A
Gapdh-Snrpn-GFP V6.5 mESC Stelzer et al., 2015 N/A
C3H10T1/2 cell line Constantinides et al., 1977 N/A
Recombinant DNA
dCas9-Tet/Dnmt This paper N/A
pgRNA This paper N/A
See “Plasmid design and construction” in METHOD DETAILS 
section
Sequence-Based Reagents
See Table S2, S3, S4, S4 for primer sequences This paper N/A
Software and Algorithms
MACS (ChIP-seq algorithms) Wu et al., 2014b http://liulab.dfci.harvard.edu/MACS/
ImageJ (Fiji) NIH http://imagej.net/Fiji
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